|Bid||41.99 x 120700|
|Ask||42.01 x 6100|
|Day's range||41.50 - 42.78|
|52-week range||40.46 - 52.82|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||12.55|
|Earnings date||06 May 2020|
|Forward dividend & yield||0.84 (1.91%)|
|Ex-dividend date||21 May 2020|
|1y target est||N/A|
It's been a good week for Fresenius SE & Co. KGaA (ETR:FRE) shareholders, because the company has just released its...
Following a tumultuous 2018 when Fresenius issued several profit warnings, last year was marked by investment and stabilisation, with the group's management pointing to an improvement from 2020 onwards. Separately-listed dialysis unit Fresenius Medical Care , which generated 49% of the group's quarterly revenue, on Wednesday reported in-line results saying record growth in home care dialysis offset the one-off effects of an ongoing legal dispute. Home care has been a growth area for the world's largest kidney dialysis provider, but it has been critical of hard targets set by President Donald Trump's administration for treating more patients with kidney disease at home.
(Bloomberg Opinion) -- It isn’t just Unilever NV that’s struggling to sell more food. Rival Nestle SA now expects to come up short of its self-imposed sales-growth target this year, and it’s counting on acquisitions to put it back on track.While Chief Executive Officer Mark Schneider met the lower end of a goal for underlying operating margin 12 months early, it will take at least another year for the owner of the Nesquik and Nespresso brands to reach and sustain its annual sales growth objective of 4-6%, partly due to the effect of disposals.It’s a rare misstep for Nestle’s first external CEO for almost 100 years. Even with the 2% drop on Thursday, the shares are up more than 40% since his arrival in January 2017, outpacing Unilever. While Schneider’s made a good start selling off underperformers and making purchases in faster growing areas, such as coffee, pet food and meat substitutes, more reshaping is needed. He has traded — either acquired or moved out of — businesses that accounted for about 12% of total sales in 2017. That’s ahead of his target for changing up 10% by the end of 2020. He’s not done yet. From here the focus will be more on acquisitions than disposals.While expanding in the right growth markets is key, Schneider should also go further in pruning the Swiss food giant. Possible culprits for offloading could be parts of the U.S. frozen foods business, especially pizzas, or some water assets, such as those mainstream brands that can’t be taken up market. The fact that Nestle wrote down the value of its Yinlu business in China could be a prelude to an exit from difficult divisions, for example making peanut milk. However, selling off these businesses may be trickier than previous disposals in confectionery, skincare and ice cream.There’s also a risk that Schneider, in an effort to turbocharge growth, becomes less disciplined when he buys. He indicated that he’s open to a wide array of options, the most promising being small or mid-sized purchases, particularly in the hot market for nutrition and metabolism. He lamented that last year was heavy on disposals, but light on purchases. That should change this year, but he shouldn’t be too eager and so strike rash deals.Schneider is comfortable in the pharmaceutical space, having led German healthcare company Fresenius SE before joining Nestle. Medical nutrition not only has higher growth prospects and margins than many food areas, but it is also less constrained by competition rules because Nestle doesn’t have such a big position. He most recently bolstered Nestle’s medical nutrition arm by acquiring gastrointestinal medication Zenpep and increased the investment in Aimmune Therapeutics Inc., which has developed a product to counter the effects of peanut allergies. It indicates that this area, particularly treatments related to the body’s metabolism, is likely to be a bigger focus.To fund any large-scale ambitions, Schneider has Nestle’s stake in L’Oreal SA, worth about 35 billion euros ($38 billion), to play with. The company has always said that it won’t part with this holding unless it has a strategic use for the proceeds, but but he seemed to be more open to an exit on Thursday. Small- to medium-sized deals wouldn’t require any change. A bigger transaction — which can’t be ruled out — might.Either way, Schneider can’t afford to take the wrong turn. Not only is activist Dan Loeb still on the register, but Nestle’s valuation has increased significantly under his tenure. The shares trade on about 22 times forward earnings, compared with about 20 times for Unilever.The premium is justified by Unilever’s recent sales stumble, as well as its slower pace of portfolio change and less focused approach to acquisitions. That doesn’t mean Nestle won’t be punished if it disappoints in the same way as its rival.To contact the author of this story: Andrea Felsted at email@example.comTo contact the editor responsible for this story: Melissa Pozsgay at firstname.lastname@example.orgThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
(Bloomberg) -- CVC Capital Partners is exploring options for its French private medical chain Elsan SAS, people familiar with the matter said.The private equity firm has been speaking with potential advisers about a sale or initial public offering of Elsan, according to the people, who asked not to be identified because the information is private. A deal could value the company at about 3 billion euros ($3.3 billion), the people said.Paris-based Elsan operates more than 120 clinics and private hospitals across France. The company employs about 25,000 people including 6,500 physicians, according to its website.CVC acquired Elsan in 2014 from private equity firms NiXEN Partners SAS and 3i Group plc for an undisclosed amount.No final decisions have been made, and CVC may decide to hold the company for longer, the people said. Representatives for CVC and Elsan declined to comment.CVC has a track record of lucrative investments in the European health-care industry. In 2016, CVC and its partners agreed to sell Spanish hospital operator IDC Salud Holding SLU to Fresenius SE for 5.76 billion euros. (Updates with CVC deal background in last paragraph)\--With assistance from Myriam Balezou.To contact the reporters on this story: Dinesh Nair in London at email@example.com;Manuel Baigorri in Hong Kong at firstname.lastname@example.org;Jan-Henrik Förster in London at email@example.comTo contact the editors responsible for this story: Ben Scent at firstname.lastname@example.org;Fion Li at email@example.comFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Let's talk about the popular Fresenius SE & Co. KGaA (ETR:FRE). The company's shares saw a double-digit share price...
While not a mind-blowing move, it is good to see that the Fresenius SE & Co. KGaA (ETR:FRE) share price has gained 20...
Stephan Sturm has been the CEO of Fresenius SE & Co. KGaA (ETR:FRE) since 2016. First, this article will compare CEO...
* European shares off 21-month highs they hit yesterday * STOXX 600 down 0.2%, DAX down 0.02% * British stocks, pound lower as election nears * S&P 500 closed at record high * Earnings in focus: Stora Enso, Fresenius, BP Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market moves: rm://firstname.lastname@example.org CLOSING SNAPSHOT: RED IS THE NEW BLACK (1720 GMT) After flying high yesterday, European bourses closed down today as weak earnings and the continuous uncertainty surrounding the UK election dampened the optimism fuelled by Monday's progress on the U.S.-China trade front. Investors avoided big bets as Boris Johnson continued to push for a pre-Christmas election which he hopes will land him a majority and the chance to finally get his Brexit deal through parliament.
The group said both Fresenius Medical Care , the world's largest provider of dialysis treatments, and drugmaker Kabi saw strong organic growth in Asia and Europe, more than offsetting weak U.S. markets. Shares in both Fresenius and Fresenius Medical Care were up about 4% in early trade on Tuesday. Analysts said investors were relieved that a summer slowdown at Helios and a further negative impact from a U.S. dialysis treatment coordination programme known as ESCO did not materialize.
Today we'll evaluate Fresenius SE & Co. KGaA (ETR:FRE) to determine whether it could have potential as an investment...
Today we'll take a closer look at Fresenius SE & Co. KGaA (ETR:FRE) from a dividend investor's perspective. Owning a...
German health care group Fresenius has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report. Sources had told Reuters in May that Fresenius had approached potential suitors about selling the unit and had hired Goldman Sachs for that purpose. "I confirm that the transfusion business will continue to be operated by Fresenius," a spokesman for the firm said in an email when asked about the report.
Today we'll evaluate Fresenius SE & Co. KGaA (FRA:FRE) to determine whether it could have potential as an investment...
Increase in profitability and industry-beating performance can be essential considerations in a stock for some...
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Josephine Mason. Investors are taking a breather this morning with most European stock futures indicating a flat open as they brace for the first U.S. interest cut in a decade expected tomorrow after the close. Breaking ranks with its euro-zone peers, London's stock futures have hit their highest in nearly a year in early deals and are currently up 0.2%, as a punishing rout in sterling amid deepening worries about a no-deal Brexit continues to lift its multinational constituents and after strong earnings from heavyweight BP.
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Josephine Mason. There's a slew of heavyweight German corporate earnings to digest this morning from Lufthansa, to HeidelbergCement to Fresenius and Bayer. The pain over ticket prices is unlikely to ease any time soon, was the message from Lufthansa which Tuesday posted a decline in second-quarter earnings, hurt by price competition on short-haul routes in Germany and Austria as well as rising fuel costs.
FMC Chief Executive Rice Powell said it had cut the savings ratio for the programme, which it uses to calculate sales and earnings "as a precautionary measure", though it maintained its overall outlook. "The savings rate is lower than we had anticipated and hoped for," Powell told analysts in a call, adding the adjustment was not part of the company's planning when it issued full-year guidance in February.
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...